A phase 1 trial of host dendritic cell infusion after allogenic stem cell transplant for prevention or treatment of relapsed disease in patients with advanced hematologic malignancies

ID Number 08-0906

Principal Investigator(s)
Keren Osman

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine the effectiveness and safety of an investigational vaccine made with specialized white blood cells called dendritic cells. To make a dendritic cell vaccine, the blood bank technician will remove some of your dendritic cells. These cells will be reproduced in the laboratory and then exposed to antigens (proteins) from your cancer cells. This combination of dendritic cells and antigens (the vaccine) will then be given to you by an intravenous (IV) infusion. The dendritic cells will work to program the T cells (a type of lymphocyte) of your immune system to attack your cancer cells. Your immune system is a protection mechanism that detects and reacts to foreign organisms and is responsible for destroying cancer cells.This investigational vaccine has not been approved for use by the Food and Drug Administration (FDA).

Contact Information
Zachary Galitzeck
(212) 241-6377

Recruiting Patients: Yes